Viridian Therapeutics licenses veligrotug, VRDN-003 to Kissei for Japan; $70M upfront, up to $315M milestones

Viridian Therapeutics, Inc.\DE

Upfront payment of $70M; up to $315M in development, regulatory, and commercial milestones.
Tiered royalties on Japan net sales in the 20s to mid-30s percent range.
Kissei gets exclusive Japan rights; Viridian retains manufacturing/supply responsibilities except limited cases.
Veligrotug (VRDN-001) and VRDN-003 are anti-IGF-1R antibodies targeting thyroid eye disease.
THRIVE and THRIVE-2 phase 3 trials for veligrotug met all primary and secondary endpoints.

item 1.01item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.